Several groups have demonstrated the feasibility of either deleting or manipulating the CD33 gene within HSCs prior to a bone marrow transplant in AML patients to enable safer treatment with anti-CD33 therapy [68, 69]. Here, CD33 is linked to acute myeloid leukemia.